4-{4-[(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl]piperazin-1-yl}-2-(thiophen-2-yl)quinazoline | 1222877-00-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-{4-[(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl]piperazin-1-yl}-2-(thiophen-2-yl)quinazoline
• 英文别名: 4-[4-(2,3-Dihydro-1,4-benzodioxin-6-ylmethyl)piperazin-1-yl]-2-thiophen-2-ylquinazoline
• CAS: 1222877-00-0
• 化学式: C₂₅H₂₄N₄O₂S
• 分子量: 444.557
• InChiKey: DHAHYMUGZPJBDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  79
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,3-二氢-1,4-苯并二噁烷-6-羧酸 在 lithium aluminium tetrahydride 、 三溴化磷 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 4-{4-[(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl]piperazin-1-yl}-2-(thiophen-2-yl)quinazoline
  参考文献：
  名称：

  Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity

  摘要：

  Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.

  DOI：

  10.1021/jm1008902

文献信息

• Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity
  作者：Juan J. Marugan、Wei Zheng、Omid Motabar、Noel Southall、Ehud Goldin、Wendy Westbroek、Barbara K. Stubblefield、Ellen Sidransky、Ronald A. Aungst、Wendy A. Lea、Anton Simeonov、William Leister、Christopher P. Austin

  DOI：10.1021/jm1008902

  日期：2011.2.24

  Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.